Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARCT NASDAQ:CNST OTCMKTS:INVVY OTCMKTS:NWBO NASDAQ:TBPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARCTArcturus Therapeutics$18.13+4.7%$15.47$8.04▼$25.88$470.32M2.38499,183 shs411,791 shsCNSTConstellation Pharmaceuticals$33.99$33.89$17.00▼$39.30$1.63B2.59940,325 shsN/AINVVYIndivior$21.85-1.8%$21.85$14.76▼$35.50$3.01B0.353,825 shs8,100 shsNWBONorthwest Biotherapeutics$0.25-2.8%$0.25$0.17▼$0.48$391.98M-1.144.45 million shs2.79 million shsTBPHTheravance Biopharma$14.40+0.7%$12.46$7.88▼$14.55$720.17M0.04533,658 shs447,517 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARCTArcturus Therapeutics+4.68%+1.63%-6.93%+47.64%-12.63%CNSTConstellation Pharmaceuticals0.00%0.00%0.00%0.00%0.00%INVVYIndivior0.00%0.00%0.00%0.00%0.00%NWBONorthwest Biotherapeutics-2.81%+0.96%+3.06%-5.99%-23.05%TBPHTheravance Biopharma+0.70%+3.45%+9.51%+35.85%+76.90%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARCTArcturus Therapeutics$18.13+4.7%$15.47$8.04▼$25.88$470.32M2.38499,183 shs411,791 shsCNSTConstellation Pharmaceuticals$33.99$33.89$17.00▼$39.30$1.63B2.59940,325 shsN/AINVVYIndivior$21.85-1.8%$21.85$14.76▼$35.50$3.01B0.353,825 shs8,100 shsNWBONorthwest Biotherapeutics$0.25-2.8%$0.25$0.17▼$0.48$391.98M-1.144.45 million shs2.79 million shsTBPHTheravance Biopharma$14.40+0.7%$12.46$7.88▼$14.55$720.17M0.04533,658 shs447,517 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARCTArcturus Therapeutics+4.68%+1.63%-6.93%+47.64%-12.63%CNSTConstellation Pharmaceuticals0.00%0.00%0.00%0.00%0.00%INVVYIndivior0.00%0.00%0.00%0.00%0.00%NWBONorthwest Biotherapeutics-2.81%+0.96%+3.06%-5.99%-23.05%TBPHTheravance Biopharma+0.70%+3.45%+9.51%+35.85%+76.90%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARCTArcturus Therapeutics 3.00Buy$50.57178.94% UpsideCNSTConstellation Pharmaceuticals 0.00N/AN/AN/AINVVYIndivior 0.00N/AN/AN/ANWBONorthwest Biotherapeutics 0.00N/AN/AN/ATBPHTheravance Biopharma 3.60Strong Buy$23.0059.72% UpsideCurrent Analyst Ratings BreakdownLatest ARCT, TBPH, INVVY, CNST, and NWBO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/12/2025TBPHTheravance BiopharmaB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$28.009/11/2025TBPHTheravance BiopharmaB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy9/4/2025ARCTArcturus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$60.008/22/2025ARCTArcturus TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$63.00 ➝ $54.008/15/2025TBPHTheravance BiopharmaZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy8/12/2025ARCTArcturus TherapeuticsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$47.00 ➝ $49.008/12/2025ARCTArcturus TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$45.00 ➝ $42.007/2/2025ARCTArcturus TherapeuticsScotiabankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform7/2/2025ARCTArcturus TherapeuticsScotiabankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Outperform$32.00 ➝ $35.006/27/2025TBPHTheravance BiopharmaBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$24.00 ➝ $25.006/17/2025TBPHTheravance BiopharmaJones TradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy$24.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARCTArcturus Therapeutics$152.31M3.23N/AN/A$8.90 per share2.04CNSTConstellation PharmaceuticalsN/AN/AN/AN/A$8.63 per shareN/AINVVYIndivior$791M3.81$1.15 per share18.94$1.45 per share15.07NWBONorthwest Biotherapeutics$1.38M276.06N/AN/A($0.07) per share-3.61TBPHTheravance Biopharma$64.38M11.26N/AN/A$3.57 per share4.03Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARCTArcturus Therapeutics-$80.94M-$2.23N/AN/AN/A-49.26%-24.87%-17.75%11/6/2025 (Estimated)CNSTConstellation Pharmaceuticals-$126.36M-$2.81N/AN/AN/AN/A-33.12%-29.92%N/AINVVYIndivior$205M$1.0520.8112.00N/AN/AN/AN/AN/ANWBONorthwest Biotherapeutics-$83.78M-$0.06N/A∞N/A-7,524.50%N/A-291.13%11/14/2025 (Estimated)TBPHTheravance Biopharma-$56.42M$0.2460.0041.14N/A16.88%6.93%3.52%11/11/2025 (Estimated)Latest ARCT, TBPH, INVVY, CNST, and NWBO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025NWBONorthwest BiotherapeuticsN/A-$0.01N/A-$0.01N/A$0.13 million8/11/2025Q2 2025ARCTArcturus Therapeutics-$1.11-$0.34+$0.77-$0.34$17.64 million$28.30 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARCTArcturus TherapeuticsN/AN/AN/AN/AN/ACNSTConstellation PharmaceuticalsN/AN/AN/AN/AN/AINVVYIndiviorN/AN/AN/AN/AN/ANWBONorthwest BiotherapeuticsN/AN/AN/AN/AN/ATBPHTheravance BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARCTArcturus TherapeuticsN/A5.905.90CNSTConstellation PharmaceuticalsN/A15.3915.39INVVYIndiviorN/AN/AN/ANWBONorthwest BiotherapeuticsN/A0.070.07TBPHTheravance BiopharmaN/A6.706.70Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARCTArcturus Therapeutics94.54%CNSTConstellation PharmaceuticalsN/AINVVYIndivior0.05%NWBONorthwest Biotherapeutics0.04%TBPHTheravance Biopharma99.10%Insider OwnershipCompanyInsider OwnershipARCTArcturus Therapeutics15.30%CNSTConstellation Pharmaceuticals43.70%INVVYIndiviorN/ANWBONorthwest Biotherapeutics8.70%TBPHTheravance Biopharma6.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARCTArcturus Therapeutics18027.16 million23.00 millionOptionableCNSTConstellation Pharmaceuticals15447.92 millionN/ANot OptionableINVVYIndivior800137.88 millionN/ANot OptionableNWBONorthwest Biotherapeutics201.51 billion1.38 billionNot OptionableTBPHTheravance Biopharma11050.36 million46.89 millionOptionableARCT, TBPH, INVVY, CNST, and NWBO HeadlinesRecent News About These CompaniesTheravance Biopharma (NASDAQ:TBPH) Stock Rating Upgraded by B. RileySeptember 15 at 5:52 AM | marketbeat.comTheravance Biopharma, Inc. (NASDAQ:TBPH) Receives $23.00 Consensus Target Price from BrokeragesSeptember 15 at 2:13 AM | americanbankingnews.comTheravance Biopharma (NASDAQ:TBPH) Shares Up 4.6% - Should You Buy?September 14 at 12:11 PM | marketbeat.comTheravance Biopharma, Inc. (NASDAQ:TBPH) Receives Average Rating of "Buy" from BrokeragesSeptember 14 at 8:19 AM | marketbeat.comB. Riley Initiates Coverage on Theravance Biopharma (NASDAQ:TBPH)September 14 at 8:14 AM | marketbeat.comTheravance Biopharma, Inc. $TBPH Shares Sold by Jacobs Levy Equity Management Inc.September 14 at 3:25 AM | marketbeat.comB. Riley Begins Coverage on Theravance Biopharma (NASDAQ:TBPH)September 13 at 3:45 AM | americanbankingnews.com46,972 Shares in Theravance Biopharma, Inc. $TBPH Bought by Cubist Systematic Strategies LLCSeptember 13 at 3:24 AM | marketbeat.comB. Riley Securities Initiates Coverage of Theravance Biopharma (TBPH) with Buy RecommendationSeptember 12, 2025 | msn.comTheravance Biopharma initiated with a Buy at B. RileySeptember 12, 2025 | msn.comTheravance Bio (TBPH) Up 9.8% Since Last Earnings Report: Can It Continue?September 11, 2025 | zacks.comInvesco Ltd. Sells 23,515 Shares of Theravance Biopharma, Inc. $TBPHSeptember 10, 2025 | marketbeat.comQ3 Earnings Estimate for TBPH Issued By Zacks ResearchSeptember 7, 2025 | marketbeat.comTheravance Biopharma, Inc. $TBPH Shares Bought by PDT Partners LLCSeptember 6, 2025 | marketbeat.comResearch Analysts Set Expectations for TBPH Q3 EarningsSeptember 6, 2025 | americanbankingnews.comTheravance Biopharma (NASDAQ:TBPH) Hits New 12-Month High - Should You Buy?September 4, 2025 | marketbeat.comTheravance Biopharma to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 2, 2025 | prnewswire.comWellington Management Group LLP Sells 43,062 Shares of Theravance Biopharma, Inc. $TBPHSeptember 2, 2025 | marketbeat.comRussell Investments Group Ltd. Has $429,000 Stake in Theravance Biopharma, Inc. $TBPHSeptember 2, 2025 | marketbeat.comVanguard Group Inc. Grows Stake in Theravance Biopharma, Inc. $TBPHSeptember 1, 2025 | marketbeat.comTheravance Biopharma, Inc. $TBPH Shares Sold by Deutsche Bank AGSeptember 1, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeARCT, TBPH, INVVY, CNST, and NWBO Company DescriptionsArcturus Therapeutics NASDAQ:ARCT$18.13 +0.81 (+4.68%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$18.19 +0.06 (+0.33%) As of 09:16 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.Constellation Pharmaceuticals NASDAQ:CNSTConstellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include Pelabresib that is in Phase 3 clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib. It is also developing CPI-0209 that is in Phase 1 dose escalation portion of a Phase 1/2 clinical trial to treat solid tumors; and CPI-482, which is in preclinical stage for cancer patients. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.Indivior OTCMKTS:INVVY$21.85 -0.40 (-1.82%) As of 06/9/2023Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in Slough, the United Kingdom.Northwest Biotherapeutics OTCMKTS:NWBO$0.25 -0.01 (-2.81%) As of 09/15/2025 03:58 PM EasternNorthwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.Theravance Biopharma NASDAQ:TBPH$14.40 +0.10 (+0.70%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$14.54 +0.14 (+0.97%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Reddit Hits Record Highs: Why Wall Street Is Taking Notice Royal Caribbean's 33% Dividend Hike Signals Deeper Growth FuelCell Energy's Stock: Is a Fundamental Breakout Underway? After a Strong Wall Street Debut, Klarna's Real Work Begins MarketBeat Week in Review – 09/08 - 09/12 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
